Biotech · Private company
Arvinas Estrogen Receptor, Inc.
Track this companyFree. Adds Arvinas Estrogen Receptor, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials135 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- PalbociclibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- VepdegestrantPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ARV-471 in combination with EverolimusPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionPHASE1 · RECRUITING · started Nov 18, 2025ClinicalTrials.gov NCT07231991 · fetched Nov 12, 2026
- A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy AdultsPHASE1 · COMPLETED · started Apr 2, 2024ClinicalTrials.gov NCT06347861 · fetched Nov 12, 2026
- A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine VepdegestrantPHASE1 · COMPLETED · started Feb 23, 2024ClinicalTrials.gov NCT06275841 · fetched Nov 12, 2026
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 19, 2024ClinicalTrials.gov NCT06206837 · fetched Nov 12, 2026
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)PHASE1_PHASE2 · TERMINATED · started Jan 10, 2024ClinicalTrials.gov NCT06125522 · fetched Nov 12, 2026
- Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Aug 9, 2023ClinicalTrials.gov NCT05909397 · fetched Nov 12, 2026
- A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy AdultsPHASE1 · COMPLETED · started Jun 12, 2023ClinicalTrials.gov NCT05930925 · fetched Nov 12, 2026
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 3, 2023ClinicalTrials.gov NCT05654623 · fetched Nov 12, 2026
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)PHASE1_PHASE2 · TERMINATED · started Mar 1, 2023ClinicalTrials.gov NCT05573555 · fetched Nov 12, 2026
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 23, 2023ClinicalTrials.gov NCT05548127 · fetched Nov 12, 2026
- A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy AdultsPHASE1 · COMPLETED · started Dec 9, 2022ClinicalTrials.gov NCT05652660 · fetched Nov 12, 2026
- ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast CancerPHASE1 · COMPLETED · started Sep 8, 2022ClinicalTrials.gov NCT05501769 · fetched Nov 12, 2026
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerPHASE1_PHASE2 · COMPLETED · started Sep 22, 2019ClinicalTrials.gov NCT04072952 · fetched Nov 12, 2026